November 27, 2024
Clinical Trials Articles
November 1, 2024
Clinical Trials Training at Women in Ophthalmology
By Christine Kay, MD, Lisa M. Nijm, MD, JD
November 1, 2024
The Pathology of Stargardt Disease and Future Treatment Horizons
By Joseph C. Giacalone, MD, PhD, Brittni A. Scruggs, MD, PhD
November 1, 2024
Clinical Trial Update November/December 2024
October 25, 2024
Gene Therapy Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 19, 2024
Ocular Insert Shows Potential as MacTel Treatment
By Jim Gallagher, senior managing editor
October 19, 2024
Eylea HD Data Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 18, 2024
Faricimab Effective in Underrepresented DME Patients
By Jim Gallagher, senior managing editor
October 18, 2024
Pegcetacoplan an Effective Treatment for Subfoveal GA
By Jim Gallagher, senior managing editor
October 18, 2024
Data Presented at AAO Support Utility of Home OCT
By Jim Gallagher, senior managing editor
October 1, 2024
Clinical Trial Update October 2024
October 1, 2024
Results of Recent Trials of Duravyu for Wet AMD
By Carl D. Regillo, MD, FACS
October 1, 2024
An Expanded Role for Faricimab?
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
October 1, 2024
An Expanded Role for Faricimab?
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
October 1, 2024
Clinical Trial Download: The Potential of Optogenetic Therapy
By Yasha Modi, MD , Allen C. Ho, MD, Sulagna Bhattacharya, MBA
October 1, 2024
Participating in Clinical Trials as a Retina Specialist
By David A. Eichenbaum, MD
October 1, 2024
The Evolution of Clinical Trial Endpoints for Wet AMD
By Ruwan Amila Silva, MD, MPhil
September 30, 2024
Data on CUO6 from ASRS 2024: The Pill that Could Treat DME
By Victor Gonzalez, MD, Michael A. Singer, MD
September 1, 2024
The Role of TNF-α Inhibitors in Managing Wet AMD
By Christian Akotoye, MD, Priya Shukla, BS, Rishi P. Singh, MD
September 1, 2024
Clinical Trial Update September 2024
September 1, 2024
Upfront: How Far We've Come
By Peter K. Kaiser, MD
September 1, 2024
Current Trials in Uveal Melanoma
By Yehonatan Weinberger, MD, Arun D. Singh, MD
September 1, 2024
New Drug Therapies for Benign Retinal Tumors
By Mary E. Aronow, MD
August 26, 2024
RHONE-X Highlights DME Disease Control and Durability with Faricimab
By Arshad M. Khanani, MD, MA, FASRS, Michael A. Singer, MD
July 25, 2024
Phase 2 LUNA Trial Data Presented at ASRS
July 25, 2024
Ellipsoid Zone Integrity at Baseline Predicts Geographic Atrophy Progression Rate
July 23, 2024
Two-year Data on Susvimo Reported at ASRS
July 19, 2024
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS
By Jennifer Ford, senior managing editor
July 18, 2024
TEASE-3 Study Data on Oral Therapy for Stargardt Disease Presented at ASRS
By Jennifer Ford, senior managing editor
July 18, 2024
Interim Phase 1 HELIOS Trial Data of Axpaxli for NPDR Presented at ASRS
By Jennifer Ford, senior managing editor
July 17, 2024
Phase 2 PRISM Trial Data on 4D-150 Gene Therapy Presented at 2024 ASRS Meeting
By Jennifer Ford, senior managing editor
July 17, 2024
Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS
By Jennifer Ford, senior managing editor
July 17, 2024
Outcomes of Faricimab in DME Study Presented at ASRS
July 10, 2024
Optogenetic Therapy Shows Promise for Retinitis Pigmentosa
July 10, 2024
APX3330 Shows Promise in Slowing DR Progression
July 10, 2024
Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
July 1, 2024
Uveitis Corner: A 2024 Update on Clinical Trials in Uveitis
By Sruthi Arepalli, MD
July 1, 2024
First Patient Dosed in Inflammasome GA Clinical Trial
By Rochelle Nataloni, contributing writer
July 1, 2024
Ocugen Meets Dosing Milestone in Stargardt Disease Trial
By Rochelle Nataloni, contributing writer
July 1, 2024
CRISPR Trial Demonstrates Potential Advances for Inherited Blindness
By Rochelle Nataloni, contributing writer
July 1, 2024
PULSAR Analysis of Aflibercept in nAMD Presented at ARVO
By Rochelle Nataloni, contributing writer
July 1, 2024
New ARCHER ANX007 in GA Treatment Findings Presented at ARVO
By Rochelle Nataloni, contributing writer
July 1, 2024
Clinical Trial Update July/August 2024
June 1, 2024
First Patient Dosed in Retinitis Pigmentosa Intravitreal Treatment Trial
By Rochelle Nataloni, contributing writer
June 1, 2024
FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder
By Rochelle Nataloni, contributing writer
June 1, 2024
Regenxbio Publishes Data Supporting One-time Use of Gene Therapy for Wet AMD
By Rochelle Nataloni, contributing writer
June 1, 2024
Ocular Therapeutix Reports Positive Top-line Phase 1 Data for Axpaxli
By Rochelle Nataloni, contributing writer
June 1, 2024
Ocugen Announces Milestones in OCU410 and OCU400 Clinical Trials
By Rochelle Nataloni, contributing writer
June 1, 2024
Post Hoc Analysis of Phase 2/3 PHOTON Trial Outcomes Presented at ARVO
By Rochelle Nataloni, contributing writer
June 1, 2024
ARCHER Trial Data Indicate ANX007 Protects Against GA Vision Loss
By Jim Gallagher, senior managing editor
June 1, 2024
DME Treatment AG-73305 Found Safe, Effective in Phase 2b Trial
By Jim Gallagher, senior managing editor
June 1, 2024
The Evolution of Clinical Trial Endpoints for Diabetic Retinopathy
By David R. Lally, MD, Jay S. Pepose, MD, PhD, George N. Magrath, MD, MBA, MS, et al.
June 1, 2024
Clinical Trial Update June 2024
May 1, 2024
Overview of Retinal Prosthesis and Future Directions
By Jade Y. Moon, MD, Richard N. Sather III, BS, Sandra R. Montezuma, MD
May 1, 2024
Clinical Trial Update May 2024
May 1, 2024
Subspecialty News May 2024
By Rochelle Nataloni, contributing writer
May 1, 2024
Upfront: The Technological Intersection of Aviation and Retina
By Peter K. Kaiser, MD
April 29, 2024
AMARONE Shows Promising Outcomes for a Novel Treatment Pathway in DME and nAMD
By Charles C. Wykoff, MD, PhD, Michael A. Singer, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
By Jim Gallagher, senior managing editor
April 1, 2024
Nesvategrast Fails to Meet Primary Efficacy Endpoint in DR:EAM Trial
By Jim Gallagher, senior managing editor
April 1, 2024
Uveitis Corner: Results of the MERIT Trial for Uveitic Macular Edema
By Sruthi Arepalli, MD, Douglas A. Jabs, MD, MBA, Nisha Acharya, MD, MS
April 1, 2024
Broader VEGF Pathway Inhibition for Wet AMD
By Mark R. Barakat, MD, Mark P. Breazzano, MD
March 25, 2024
Positive Results for EYP-1901 in DAVIO 2, and a Look Forward to Phase 3
By Carl D. Regillo, MD, FACS, Michael A. Singer, MD
March 1, 2024
Clinical Trial Update March 2024
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
February 16, 2024
Retinal Physician eUpdate - February 16, 2024
By Steve Lenier
January 1, 2024
Subspecialty News January/February 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
Therapies for Geographic Atrophy: Safety First
By Hashem Ghoraba, Sumit Sharma, MD
January 1, 2024
Breaking News: 12-month Data for Faricimab for Retinal Vein Occlusion
By Ramin Tadayoni, MD, PhD, Michael A. Singer, MD
January 1, 2024
A Summary of the MERIT Trial: Intravitreal Therapy for Uveitic Macular Edema
By Sruthi Arepalli, MD
November 1, 2023
UVEITIS CORNER: A Year in Review for Uveitis
By Sruthi Arepalli, MD
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
The Diabetic Retinopathy Pipeline
By Nathalie E. Perez, BS, Lauren C. Kiryakoza, MD, Jayanth Sridhar, MD
October 1, 2023
Clinical Trial Update October 2023
September 1, 2023
UPFRONT: Medicine Evolves
By Peter K. Kaiser, MD
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
UPFRONT: Failure Is Not Trying
By Peter K. Kaiser, MD
June 1, 2023
SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
By Rochelle Nataloni, contributing writer
June 1, 2023
Clinical Trial Update June 2023
May 1, 2023
SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
Overcoming Retina Clinical Trial Challenges With Tailored Solutions
By Marcus J. Solomon, MD
April 1, 2023
NEW PRODUCT APPLICATIONS: RetinAI Discovery Core Platform Accelerates Research
By Karen Appold, contributing writer
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
Key Questions at the Heart of Inherited Retinal Disease Gene Therapy Innovation
By Thomas A. Mendel, MD, PhD
March 1, 2023
A Basic Primer on Gene Therapy
By Thomas A. Ciulla, MD, MBA, Aumer Shughoury, MD
March 1, 2023
Gene Therapy for Dry AMD
By Ehsan Rahimy, MD, Austen N. Knapp, MD
March 1, 2023
UPFRONT: Gene Therapy's Price Tag
By Peter K. Kaiser, MD
March 1, 2023
SUBSPECIALTY NEWS: First drug approved for ROP, PDT laser approved, inequities in ophthalmology research, and more.
By Rochelle Nataloni, contributing writer
March 1, 2023
Clinical Trial Update March 2023
February 2, 2023
FDA Approves Syfovre as First Treatment for Geographic Atrophy
February 1, 2023
Complement Inhibition in Geographic Atrophy
By William Carrera, MD, MS, Jeffrey S. Heier, MD
February 1, 2023
Clinical Trial Update: Special Edition 2023
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
Clinical Trial Update January/February 2023
November 1, 2022
Clinical Trial Update November/December 2022
October 1, 2022
Current Clinical Trials in Uveitis
By Sruthi Arepalli, MD
October 1, 2022
SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.
By Rochelle Nataloni, contributing writer
October 1, 2022
CLINICAL TRIAL DOWNLOAD: Data From the Phase 2b Trial of OPT-302
By Yasha Modi, MD , Jason S. Slakter, MD, Aleksandra V. Rachitskaya, MD, FASRS, et al.
October 1, 2022
Clinical Trial Update October 2022
September 1, 2022
Clinical Trial Update September 2022
August 1, 2022
Clinical Trial Update Special Edition 2022
June 1, 2022
UPFRONT: Bring ARVO Back to Its Roots
By Peter K. Kaiser, MD
June 1, 2022
Clinical Trial Update June 2022
May 1, 2022
Clinical Trials in Retinal Vein Occlusion
By Neesurg Mehta, MD, Susanna S. Park, MD, PhD
May 1, 2022
Clinical Trial Update May 2022
April 1, 2022
Photobiomodulation as an Innovative and Promising Treatment for Retinal Disease
By Marion R. Munk, MD, PhD, FEBO, Krisztina Valter, MD, PhD
April 1, 2022
Clinical Trial Update April 2022
March 1, 2022
FUTURE FILE: Highlighting innovative early-stage and preclinical concepts in retina
By Jerry Helzner, contributing editor
March 1, 2022
SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
By Rochelle Nataloni, contributing writer
March 1, 2022
Clinical Trial Update March 2022
Advertisement
Recommendations
Advertisement